France's GenSight Biologics H1 net loss widens on higher R&D expenses

Gensight Biologics SA

29/09/2026 23:48

Overview
France biopharma firm's H1 2026 IFRS revenue negative on rebates, despite €6.5 mln cash collected
Net loss for H1 2026 widened to €10.3 mln; loss per share unchanged at €0.05
Company flagged material uncertainty over going concern due to need for additional funding

Outlook
Company estimates net funding requirement of about €16 mln for RECOVER Phase III trial and manufacturing
RECOVER Phase III trial expected to start in H2 2027, subject to securing necessary financing
Company warns of material uncertainty about ability to continue as going concern if funding not secured

Result Drivers
EARLY ACCESS REVENUE - Collections from paid early access programs in France and Israel reduced operating cash burn, per CFO Jan Eryk Umiastowski
ACCOUNTING CHANGES - Negative IFRS revenue driven by accrued rebates and a one-off non-cash change in accounting estimate
R&D EXPENSES - Higher research and development costs due to expanded teams and manufacturing technology transfer

Company press release: ID:nBw9GP5xxa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Loss Per Share
 
EUR 0.05
 
H1 Net Loss
 
EUR 10.30 mln
 

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Gensight Biologics SA is €0.31, about 156.7% above its September 28 closing price of €0.12

Reuters Recommended Reads
Sept 29 - France's MaaT Pharma H1 operating loss widens on higher R&D costs
Sept 28 - France's Genfit H1 revenue falls due to absence of milestone payments 
Sept 28 - UK's Hemogenyx Pharmaceuticals H1 loss widens on share-based payments

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)